{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:00:08Z","timestamp":1793412008401,"version":"4.5.0"},"reference-count":79,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HAB"],"published-print":{"date-parts":[[2024,7,24]]},"abstract":"<jats:p>OBJECTIVE: Asthma is a major global disease affecting adults and children, which can lead to hospitalization and death due to breathing difficulties. Although targeted monoclonal antibody therapies have revolutionized treatment of severe asthma, some patients still fail to respond. Here we critically evaluate the literature on biologic therapy failure in asthma patients with particular reference to anti-drug antibody production, and subsequent loss of response, as the potential primary cause of drug failure in asthma patients. RECENT FINDINGS: Encouragingly, asthma in most cases responds to treatment, including the use of an increasing number of biologic drugs in moderate to severe disease. This includes monoclonal antibody inhibitors of immunoglobulin E and cytokines, including interleukin 4, 5, or 13 and thymic stromal lymphopoietin. These limit mast cell and eosinophil activity that cause the symptomatic small airways obstruction and exacerbations. SUMMARY: Despite humanization of the antibodies, it is evident that benralizumab; dupilumab; mepolizumab; omalizumab; reslizumab and tezepelumab all induce anti-drug antibodies to some extent. These can contribute to adverse events including infusion reactions, serum sickness, anaphylaxis and potentially disease activity due to loss of therapeutic function. Monitoring anti-drug antibodies (ADA) may allow prediction of future treatment-failure in some individuals allowing treatment cessation and switching therefore potentially limiting disease breakthrough.<\/jats:p>","DOI":"10.3233\/hab-240002","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T11:51:12Z","timestamp":1718970672000},"page":"121-128","source":"Crossref","is-referenced-by-count":1,"title":["Immunogenicity of biologics used in the treatment of asthma"],"prefix":"10.1177","volume":"32","author":[{"given":"Omario A.M.","family":"Neunie","sequence":"first","affiliation":[{"name":"Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK"},{"name":"Centre for Oral Immunobiology and Regenerative Medicine, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wardah","family":"Rabbani","sequence":"additional","affiliation":[{"name":"Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Baker","sequence":"additional","affiliation":[{"name":"Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma S.","family":"Chambers","sequence":"additional","affiliation":[{"name":"Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Pfeffer","sequence":"additional","affiliation":[{"name":"William Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK"},{"name":"Department of Respiratory Medicine, Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angray S.","family":"Kang","sequence":"additional","affiliation":[{"name":"Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK"},{"name":"Centre for Oral Immunobiology and Regenerative Medicine, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/HAB-240002_ref1","doi-asserted-by":"crossref","first-page":"983852","DOI":"10.3389\/fimmu.2022.983852","article-title":"Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives.","volume":"13","author":"Kardas","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.3233\/HAB-240002_ref2","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1378\/chest.130.1_suppl.4S","article-title":"The global burden of asthma.","volume":"130","author":"Braman","year":"2006","journal-title":"Chest"},{"key":"10.3233\/HAB-240002_ref3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12916-016-0657-8","article-title":"The epidemiology, healthcare and societal burden and costs of asthma in the UK and its member nations: analyses of standalone and linked national databases.","volume":"14","author":"Mukherjee","year":"2016","journal-title":"BMC Med"},{"key":"10.3233\/HAB-240002_ref4","unstructured":"GBD 2019 Diseases and Injuries Collaborators, Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 396 (2020), 1204\u201322."},{"key":"10.3233\/HAB-240002_ref5","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.3389\/fimmu.2020.02106","article-title":"What can parasites tell us about the pathogenesis and treatment of asthma and allergic diseases.","volume":"11","author":"Bohnacker","year":"2020","journal-title":"Front Immunol"},{"key":"10.3233\/HAB-240002_ref6","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","article-title":"The Cytokines of Asthma.","volume":"50","author":"Lambrecht","year":"2019","journal-title":"Immunity"},{"key":"10.3233\/HAB-240002_ref7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1083\/jcb.201401050","article-title":"The cell biology of asthma.","volume":"205","author":"Erle","year":"2014","journal-title":"J Cell Biol"},{"key":"10.3233\/HAB-240002_ref8","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the pathophysiology of severe asthma.","volume":"10","author":"Pelaia","year":"2019","journal-title":"Front Physiol"},{"key":"10.3233\/HAB-240002_ref9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3121\/cmr.2.3.155","article-title":"Categorizing asthma severity: an overview of national guidelines.","volume":"2","author":"Colice","year":"2004","journal-title":"Clin Med Res"},{"key":"10.3233\/HAB-240002_ref10","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.jaip.2023.05.047","article-title":"Response to biologics and clinical remission in the adult german asthma net severe asthma registry cohort.","volume":"11","author":"Milger","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.3233\/HAB-240002_ref11","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jaip.2023.05.044","article-title":"Impact of initiating biologics in patients with severe asthma on long-term oral corticosteroids or frequent rescue steroids (GLITTER): Data from the international severe asthma registry.","volume":"11","author":"Chen","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.3233\/HAB-240002_ref12","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies.","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front Immunol"},{"key":"10.3233\/HAB-240002_ref13","doi-asserted-by":"crossref","first-page":"e767","DOI":"10.1212\/NXI.0000000000000767","article-title":"Detecting and predicting neutralization of alemtuzumab responses in MS.","volume":"7","author":"Saxena","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.3233\/HAB-240002_ref14","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jaip.2022.12.046","article-title":"Incidence of anti-drug antibodies to monoclonal antibodies in asthma: a systematic review and meta-analysis.","volume":"11","author":"Chen","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.3233\/HAB-240002_ref15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fimmu.2016.00021","article-title":"Immunogenicity to biotherapeutics \u2013 The role of anti-drug immune complexes.","volume":"7","author":"Krishna","year":"2016","journal-title":"Front Immunol"},{"key":"10.3233\/HAB-240002_ref16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fimmu.2020.00124","article-title":"The irony of humanization: alemtuzumab, the first, but one of the most immunogenic, humanized monoclonal antibodies.","volume":"11","author":"Baker","year":"2020","journal-title":"Front Immunol"},{"key":"10.3233\/HAB-240002_ref17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.anai.2015.04.014","article-title":"Anaphylaxis and serum sickness in patients receiving omalizumab: reviewing the data in light of clinical experience.","volume":"1115","author":"Harrison","year":"2015","journal-title":"Ann Allerg Asthma Im"},{"key":"10.3233\/HAB-240002_ref18","doi-asserted-by":"crossref","unstructured":"G.A.C. Isabwe, L.D. Sanchez and M. Castells, Management of adverse reactions to biologic agents. Allergy Asthma Proc 38 (2017), 409\u201318.","DOI":"10.2500\/aap.2017.38.4085"},{"key":"10.3233\/HAB-240002_ref19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/1744666X.2020.1724089","article-title":"Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases.","volume":"16","author":"Jackson","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"10.3233\/HAB-240002_ref20","doi-asserted-by":"crossref","first-page":"e12038","DOI":"10.1002\/clt2.12038","article-title":"Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.","volume":"11","author":"Li","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"10.3233\/HAB-240002_ref21","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1084\/jem.170.6.2153","article-title":"The immunogenicity of chimeric antibodies.","volume":"170","author":"Bruggemann","year":"1989","journal-title":"J. Exp Med."},{"key":"10.3233\/HAB-240002_ref22","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions.","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs."},{"key":"10.3233\/HAB-240002_ref23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40259-020-00465-4","article-title":"Immunogenicity challenges associated with subcutaneous delivery of therapeutic proteins.","volume":"35","author":"Jarvi","year":"2021","journal-title":"BioDrugs."},{"key":"10.3233\/HAB-240002_ref24","first-page":"69","article-title":"Anti-drug antibody validation testing and reporting harmonization.","volume":"24","author":"Myler","year":"2021","journal-title":"AAPS J"},{"key":"10.3233\/HAB-240002_ref25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/FTD.0000000000000419","article-title":"Immunoassays for measuring serum concentrations of monoclonal antibodies and anti-biophar-maceutical antibodies in patients.","volume":"39","author":"Darrouzain","year":"2017","journal-title":"Ther Drug Monit"},{"key":"10.3233\/HAB-240002_ref26","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","article-title":"AFFIRM and SENTINEL Investigators. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.","volume":"69","author":"Calabresi","year":"2007","journal-title":"Neurology"},{"key":"10.3233\/HAB-240002_ref27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/imm.12879","article-title":"Alemtuzumab depletion failure can occur in multiple sclerosis.","volume":"154","author":"Dubuisson","year":"2018","journal-title":"Immunology."},{"key":"10.3233\/HAB-240002_ref28","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41598-020-58041-3","article-title":"GloBody Technology: Detecting Anti-Drug Antibody against VH\/VL domains.","volume":"19","author":"Saxena","year":"2020","journal-title":"Sci Rep"},{"key":"10.3233\/HAB-240002_ref29","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma.","volume":"371","author":"Ortega","year":"2014","journal-title":"New Engl J Med"},{"key":"10.3233\/HAB-240002_ref30","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/psp4.12667","article-title":"Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma.","volume":"10","author":"Zhang","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"10.3233\/HAB-240002_ref31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.3233\/HAB-240002_ref32","doi-asserted-by":"crossref","first-page":"765747","DOI":"10.3389\/fimmu.2021.765747","article-title":"How to prevent and mitigate hypersensitivity reactions to biologicals induced by anti-drug antibodies?","volume":"12","author":"Vultaggio","year":"2021","journal-title":"Front Immunol"},{"key":"10.3233\/HAB-240002_ref33","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.3390\/biomedicines11123108","article-title":"Managing severe adverse reactions to biologicals in severe asthma.","volume":"11","author":"Balan","year":"2023","journal-title":"Biomedicines"},{"key":"10.3233\/HAB-240002_ref34","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3892\/etm.2021.10381","article-title":"Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach.","volume":"22","author":"Pintea","year":"2021","journal-title":"Exp Ther Med"},{"key":"10.3233\/HAB-240002_ref35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2174\/157488611798918692","article-title":"Successful desensitization of three patients with hypersensitivity reactions to omalizumab.","volume":"6","author":"Owens","year":"2011","journal-title":"Curr Drug Saf"},{"key":"10.3233\/HAB-240002_ref36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2125.2009.03401.x","article-title":"Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma.","volume":"68","author":"Lowe","year":"2009","journal-title":"Br J Clin Pharmacol."},{"key":"10.3233\/HAB-240002_ref37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/2049-6958-9-23","article-title":"Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review.","volume":"9","author":"D\u2019Amato","year":"2014","journal-title":"Multidiscip Respir Med"},{"key":"10.3233\/HAB-240002_ref38","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.iac.2020.06.004","article-title":"Biologics for atopic dermatitis.","volume":"40","author":"Boguniewicz","year":"2020","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.3233\/HAB-240002_ref39","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.","volume":"18","author":"Sol\u00e8r","year":"2001","journal-title":"Eur Respir J"},{"key":"10.3233\/HAB-240002_ref40","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immun"},{"key":"10.3233\/HAB-240002_ref41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4168\/aair.2016.8.4.319","article-title":"Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study.","volume":"8","author":"Li","year":"2016","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.3233\/HAB-240002_ref42","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1093\/milmed\/usz357","article-title":"A Case of Serum Sickness-Like Reaction in an Adult Treated with Omalizumab.","volume":"185","author":"Weiss","year":"2020","journal-title":"Mil Med"},{"key":"10.3233\/HAB-240002_ref43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1208\/s12248-015-9821-x","article-title":"Evaluation of IgE Antibodies to Omalizumab (Xolair(R)) and Their Potential Correlation to Anaphylaxis.","volume":"18","author":"Baker","year":"2016","journal-title":"AAPS J."},{"key":"10.3233\/HAB-240002_ref44","doi-asserted-by":"crossref","first-page":"593748","DOI":"10.3389\/fimmu.2020.593748","article-title":"Engineering of Humanized Antibodies Against Human Interleukin 5 Receptor Alpha Subunit That Cause Potent Antibody-Dependent Cell-Mediated Cytotoxicity.","volume":"11","author":"Kim","year":"2020","journal-title":"Front Immunol"},{"key":"10.3233\/HAB-240002_ref45","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function.","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J Allergy Clin Immunol."},{"key":"10.3233\/HAB-240002_ref46","doi-asserted-by":"crossref","first-page":"2004306","DOI":"10.1183\/13993003.04306-2020","article-title":"Novel mechanisms of action contributing to benralizumab\u2019s potent anti-eosinophilic activity.","volume":"59","author":"Dagher","year":"2022","journal-title":"Eur Respir J."},{"key":"10.3233\/HAB-240002_ref47","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.3233\/HAB-240002_ref48","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.3233\/HAB-240002_ref49","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaci.2018.08.031","article-title":"Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.","volume":"143","author":"Busse","year":"2019","journal-title":"J Allergy Clin Immun"},{"key":"10.3233\/HAB-240002_ref50","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S2213-2600(17)30190-X","article-title":"Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"5","author":"Ferguson","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.3233\/HAB-240002_ref51","first-page":"A37","article-title":"S54 Evidence of drug antibody development in severe eosinophilic asthmatics treated with benralizumab.","volume":"74","author":"Thomson","year":"2019","journal-title":"Thorax"},{"key":"10.3233\/HAB-240002_ref52","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Resp Med"},{"key":"10.3233\/HAB-240002_ref53","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"key":"10.3233\/HAB-240002_ref54","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.","volume":"150","author":"Corren","year":"2016","journal-title":"Chest."},{"key":"10.3233\/HAB-240002_ref55","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S2213-2600(19)30372-8","article-title":"Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.","volume":"8","author":"Bernstein","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.3233\/HAB-240002_ref56","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jaci.2013.11.026","article-title":"Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis.","volume":"133","author":"Haldar","year":"2014","journal-title":"J Allergy Clin Immun"},{"key":"10.3233\/HAB-240002_ref57","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma.","volume":"371","author":"Bel","year":"2014","journal-title":"New Eng J Med"},{"key":"10.3233\/HAB-240002_ref58","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin Ther."},{"key":"10.3233\/HAB-240002_ref59","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1165\/ajrcmb.10.5.8179909","article-title":"Interleukin-4, interleukin-5, and interleukin-6 and tumor-necrosis-factor-alpha in normal and asthmatic airways \u2013 Evidence for the human mast-cell as a source of these cytokines.","volume":"10","author":"Bradding","year":"1994","journal-title":"Am J Resp Cell Mol"},{"key":"10.3233\/HAB-240002_ref60","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1080\/21645515.2019.1582403","article-title":"A review of dupilumab in the treatment of atopic diseases.","volume":"15","author":"Thibodeaux","year":"2019","journal-title":"Hum Vacc Immunother"},{"key":"10.3233\/HAB-240002_ref61","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.","volume":"378","author":"Castro","year":"2018","journal-title":"New Engl J Med."},{"key":"10.3233\/HAB-240002_ref62","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis A Phase 3 Randomized Clinical Trial.","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.3233\/HAB-240002_ref63","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjd.21867","article-title":"Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials.","volume":"187","author":"Simpson","year":"2022","journal-title":"Brit J Dermatol"},{"key":"10.3233\/HAB-240002_ref64","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/13543784.2023.2215425","article-title":"Investigational anti IL-13 asthma treatments: a 2023 update.","volume":"32","author":"Matera","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"10.3233\/HAB-240002_ref66","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma.","volume":"378","author":"Rabe","year":"2018","journal-title":"New Engl J Med."},{"key":"10.3233\/HAB-240002_ref67","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.alit.2020.04.002","article-title":"Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study.","volume":"69","author":"Tohda","year":"2020","journal-title":"Allergol Int."},{"key":"10.3233\/HAB-240002_ref69","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma.","volume":"385","author":"Wechsler","year":"2021","journal-title":"N Engl J Med"},{"key":"10.3233\/HAB-240002_ref70","doi-asserted-by":"crossref","first-page":"1149203","DOI":"10.3389\/fimmu.2023.1149203","article-title":"T-helper cells and their cytokines in pathogenesis and treatment of asthma.","volume":"14","author":"Ji","year":"2023","journal-title":"Front Immunol"},{"key":"10.3233\/HAB-240002_ref71","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/meth.1996.0392","article-title":"Interleukin-5 and human B lymphocytes.","volume":"11","author":"Baumann","year":"1997","journal-title":"Methods."},{"key":"10.3233\/HAB-240002_ref72","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.179.1.135","article-title":"Interleukin 13 is a B cell stimulating factor.","volume":"179","author":"Defrance","year":"1994","journal-title":"J Exp Med"},{"key":"10.3233\/HAB-240002_ref73","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF02919735","article-title":"Functions of interleukin-4 on human B lymphocytes.","volume":"10","author":"Banchereau","year":"1991","journal-title":"Immunol Res"},{"key":"10.3233\/HAB-240002_ref74","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.4049\/jimmunol.2200922","article-title":"Requirements of IL-4 during the generation of B cell memory.","volume":"210","author":"Chakma","year":"2023","journal-title":"J Immunol"},{"key":"10.3233\/HAB-240002_ref75","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.anai.2020.10.008","article-title":"Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY.","volume":"126","author":"Corren","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.3233\/HAB-240002_ref76","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma.","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med."},{"key":"10.3233\/HAB-240002_ref77","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2147\/JAA.S378062","article-title":"Tezepelumab for patients with severe uncontrolled asthma: a systematic review and meta-analysis.","volume":"15","author":"Zoumot","year":"2022","journal-title":"J Asthma Allergy."},{"key":"10.3233\/HAB-240002_ref78","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/cpt.1371","article-title":"Relationship between benralizumab exposure and efficacy for patients with severe eosinophilic asthma.","volume":"106","author":"Chia","year":"2019","journal-title":"Clin Pharmacol Ther."},{"key":"10.3233\/HAB-240002_ref79","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bcp.15002","article-title":"A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma.","volume":"88","author":"Singh","year":"2022","journal-title":"Br J Clin Pharmacol."},{"key":"10.3233\/HAB-240002_ref80","first-page":"A49","article-title":"Biologic therapy practices in severe asthma; Outcomes from the UK severe asthma registry and survey of specialist opinion.","volume":"77","author":"Mansur","year":"2022","journal-title":"Thorax"},{"key":"10.3233\/HAB-240002_ref81","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JAA.S328653","article-title":"Real world biologic use and switch patterns in severe asthma: data from the international severe asthma registry and the US CHRONICLE study.","volume":"15","author":"Menzies-Gow","year":"2022","journal-title":"J Asthma Allergy"}],"container-title":["Human Antibodies"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/HAB-240002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:22:47Z","timestamp":1777447367000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/HAB-240002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":79,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/hab-240002","relation":{},"ISSN":["1875-869X","1093-2607"],"issn-type":[{"value":"1875-869X","type":"electronic"},{"value":"1093-2607","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,24]]}}}